By Deena Beasley Feb 10 (Reuters) - Gilead Sciences on Tuesday issued a 2026 financial forecast that was at the low end of ...

Gilead has secured another synthetic lethal therapy, handing over $80 million upfront for the global rights to a clinic-ready cancer drug from China’s Genhouse Bio. | Gilead has secured another ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best immunotherapy stocks to buy according to hedge funds. Gilead Sciences, Inc. (NASDAQ:GILD) announced its fiscal Q4 and full year 2025 results on ...

Gilead Sciences ended the fourth quarter with results that exceeded Wall Street revenue expectations, yet the market ...

The Foster City Planning Commission is voicing support in the next phase of approval for the longtime Gilead campus expansion project.

US biotech Gilead Sciences (Nasdaq: GILD) has agreed a global licensing deal worth up to $1.5 billion with China’s Genhouse ...

Gilead Sciences (NasdaqGS:GILD) plans to present late breaking data at CROI 2026 on a new investigational single tablet HIV regimen. The company will also share the first HIV cure clinical program ...

Gilead Sciences Inc. GILD shares slipped in Tuesday's extended trading after the company released its fourth-quarter earnings ...

With 10 launches planned in the coming quarters, Gilead isn’t feeling the same acquisition urgency as its pharma peers—though the prospect of a takeover isn’t off the table.

GIlead Sciences (GILD) stock is trading at record highs after announcing a top- and bottom-line beat for the fourth quarter ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which said ...